Laimei Pharmaceuticals: 300006 Laimei Pharmaceuticals Investor Relations Management Information 20240403
Laimei Pharmaceutical: Announcement on participating companies obtaining approval notices for drug clinical trials
Laimei Pharmaceuticals: Announcement on holding the 2023 Online Results Briefing
Laimei Pharmaceuticals: Internal Control Verification Report
Laimei Pharmaceutical: Announcement of Board Resolutions
Laimei Pharmaceuticals: 2023 Supervisory Committee Work Report
Laimei Pharmaceuticals: Special opinion of the board of directors on the sole director's independence assessment
Laimei Pharmaceuticals: Guojin Securities's inspection opinions on Laimei Pharmaceuticals' 2023 internal control evaluation report
Laimei Pharmaceuticals: Announcement on changes in accounting policies
Laimei Pharmaceutical: Supervisory Board Resolutions Announcement
Laimei Pharmaceuticals: Special Audit Opinions on Business Income Deduction Matters
Laimei Pharmaceutical: Announcement on the estimated amount of external guarantee for 2024
Laimei Pharmaceutical: Special Audit Instructions for Controlling Shareholders and Other Related Parties
Laimei Pharmaceutical: 2023 Independent Director Debriefing Report (Chen Xujiang)
Laimei Pharmaceutical: 2023 Independent Director Debriefing Report (Chen Geng)
Laimei Pharmaceutical: 2023 Independent Director Debriefing Report (Li Changbi)
Laimei Pharmaceuticals: 2023 Annual Audit Report
Laimei Pharmaceuticals: Guojin Securities's inspection opinions on the issuance of restricted shares by Laimei Pharmaceuticals to specific targets and lifting the listing and circulation of restricted shares
Laimei Pharmaceutical: Announcement on obtaining a drug registration certificate
Laimei Pharmaceutical: Announcement of Resolutions of the 35th Meeting of the Fifth Board of Directors
No Data